Press Releases

03.20.2019

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics

03.19.2019

Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer

03.19.2019

Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts

03.17.2019

AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention

03.11.2019

U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1

03.08.2019

European Medicines Agency Validates Application for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

03.05.2019

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

03.04.2019

Pfizer Prices $5,000,000,000 Debt Offering

03.01.2019

Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

02.28.2019

Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older

02.19.2019

Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials

02.19.2019

Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®*